alexa Comparison of Combined Bevacizumab plus Dexamethasone V
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Comparison of Combined Bevacizumab plus Dexamethasone Vs. Ranibizumab Monotherapy as First-Line Therapy in Patients with Treatment Naive Neovascular Age-Related Macular Degeneration in Real-Life Clinical Practice: A Retrospective Case-Series Analysis

Nikolaos Vakalis*, George Echiadis, Ioannis Deligiannis, Stayros Giannikakis and Ioannis Papaefthymiou

Department of Ophthalmology, Naval Hospital of Athens, Greece

*Corresponding Author:
Vakalis Nikolaos
Department of Ophthalmology
Naval Hospital of Athens, Greece
Tel: 00306974850124
E-mail: [email protected]

Received date: March 27, 2017; Accepted date: April 04, 2017; Published date: April 06, 2017

Citation: Vakalis N, Echiadis G, Deligiannis I, Giannikakis S, Papaefthymiou I (2017) Comparison of Combined Bevacizumab plus Dexamethasone Vs. Ranibizumab Monotherapy as First-Line Therapy in Patients with Treatment Naive Neovascular Age-Related Macular Degeneration in Real-Life Clinical Practice: A Retrospective Case-Series Analysis. J Clin Exp Ophthalmol 8:644. doi: 10.4172/2155-9570.1000644

Copyright: © 2017 Vakalis N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Purpose: To identify the differences between combination bevacizumab plus dexamethasone and ranibizumab in treatment naïve neovascular age-related macular degeneration in terms of functional/morphological outcomes and number of injections when evaluated in real-life clinical practice.

Methods: We compared two groups of patients either receiving intravitreal bevacizumab (1.25 mg) plus dexamethasone sodium phosphate (0.2 mg) or intravitreal ranibizumab (0.5 mg) over a 12 month period. The former, Group A, received treatment at baseline and followed a pro re nata (PRN) regimen. The latter, Group B, received treatment at baseline followed by two additional monthly injections as per the universally accepted protocol whilst continuing treatment on PRN regimen thereafter. Best-corrected visual acuity (BCVA), intraocular pressure (IOP), slit-lamp fundus examination and central macular thickness (CMT) via optical coherence tomography (OCT) were recorded at the initial visit (Baseline, BSL) and at each subsequent follow-up visit.

Results: CMT at BSL was 362.8 ± 45.4 μm in Group A and 358.3 ± 47.2 μm in Group B. At the end of the data analysis, CMT was improved substantially in both groups (246.1 ± 42.4 μm in Group A, 254.9 ± 21.2 μm in Group B), while BCVA improved as well (From 0.87 ± 0.15 logMAR to 0.48 ± 0.15 in Group A, from 0.81 ± 0.20 logMAR to 0.52 ± 0.10 in Group B). Group A received 248 injections, whereas Group B received 313.

Conclusion: Combination treatment with DSP and bevacizumab provided the same efficacy and allowed a statistically significant reduction in the frequency of injections compared with ranibizumab monotherapy.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version